Preclinical Testing of SSA Compounds in a Model of Pancreatic Neuroendocrine Tumors to Optimize Scheduling and Drug Exposition

#2081

Introduction: Somatostatin analogues (SSA) such as Octreotide and Lanreotide have demonstrated a significant benefit in Neuroendocrine Tumors, particularly in the well/moderately differentiated types. Nevertheless, there are still several aspects of SSA treatments that remain unsolved, such as drug exposition in patients and schedule optimization.

Aim(s): This study will evaluate diverse schedules and drug exposition protocols of SSA compounds in a transgenic mouse model of pancreatic NETs (pNETs).

Materials and methods: The transgenic model of pNETs (RIP1Tag2) will be used to test the efficacy of Octreotide and other SSA compounds and formulations at 1, 2 and 2.5 µg/kg/h by minipump infusion (Alzet pumps). Treatment will start at 12 weeks of age, when tumors are already fully formed.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Casanovas O

Authors: Martínez-López A, Pinto J, Lachamp L, Cabello F, Cherif-Cheikh R,

Keywords: Somatostatin Analogs, Octreotide, pNETs, dose scheduling.,

To read the full abstract, please log into your ENETS Member account.